600272.SH上海证券交易所 · 主板 Main
Shanghai Kai Kai 开开实业
Pharmaceutical Distribution 医药商业
¥15.24−¥0.57 · −3.61%
Open 开盘
¥15.52
High 最高
¥17.16
Low 最低
¥15.12
Prev Close 昨收
¥15.81
Volume 成交量
3,130.6万股
Turnover 成交额
¥5.01亿
Mkt Cap 总市值
¥40亿
P/E 市盈率
171.3×
Recent Activity 近期动态All Filings 全部公告 →
6 significant filings since 30 May 2026: 4 on regulatory inquiry, 1 on earnings pre-announcement and 1 on dividend. The latest, on 27 Aug 2026: 关于上海开开实业股份有限公司股票交易异常波动的问询函的回函.
自 30 May 2026 起有 6 份重大公告：regulatory inquiry 4 份、earnings pre-announcement 1 份、dividend 1 份。最新一份（27 Aug 2026）：关于上海开开实业股份有限公司股票交易异常波动的问询函的回函。
Price History 价格走势
1 session 个交易日, Thu 24 Sep 2026 · Live one-minute prices · High 最高 ¥16.88 · Low 最低 ¥15.14 · −3.61% on the previous close of ¥15.8115.2515.5015.7516.0016.2516.5016.75
Volume 成交量
2.5万
09:3010:3613:1214:1915:30
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Pharmaceutical Distribution 医药商业 · 30 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥40亿 | ¥59亿 | 8th lowest of 30 · 30 家中第 8 低 | |
| Trailing P/E 市盈率 | 171.3x | 22.9x | 2nd highest of 25 · 25 家中第 2 高 | |
| P/B 市净率 | 5.0x | 1.2x | 2nd highest of 30 · 30 家中第 2 高 | |
| Revenue Growth 营收增速 | 5.8% | 0.3% | 4th highest of 30 · 30 家中第 4 高 | |
| Profit Growth 净利增速 | 88.3% | -7.2% | 2nd highest of 30 · 30 家中第 2 高 | |
| Gross Margin 毛利率 | 14.6% | 11.2% | 14th highest of 30 · 30 家中第 14 高 | |
| Net Margin 净利率 | 5.1% | 1.6% | 6th highest of 30 · 30 家中第 6 高 | |
| Return on Equity 净资产收益率 | 2.8% | 3.0% | 15th lowest of 30 · 30 家中第 15 低 | |
| Debt to Assets 资产负债率 | 52.5% | 61.0% | 9th lowest of 30 · 30 家中第 9 低 | |
| Grade Score 评级得分 | 71 | 47 | 3rd highest of 30 · 30 家中第 3 高 |
Statement figures are for the period to 30 Jun 2026, filed by 30 of 30 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，30 家同业中 30 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shanghai Pharma 上海医药 | ¥594亿 | 12.4x | 0.8x | 4.2% | 2.9% | 4.5% | C |
| Yifeng Pharmacy 益丰药房 | ¥268亿 | 15.2x | 2.3x | 3.5% | 8.8% | 8.0% | B |
| Jointown 九州通 | ¥244亿 | 12.1x | 0.9x | 7.6% | 1.4% | 4.2% | D |
| DaShenLin Pharmaceutical Group 大参林 | ¥200亿 | 14.7x | 2.6x | 3.5% | 7.2% | 11.6% | B |
| China National Medicines 国药股份 | ¥194亿 | 10.1x | 1.0x | 4.3% | 3.3% | 4.7% | C |
| Qingdao Baheal Medical 百洋医药 | ¥133亿 | 24.7x | 5.8x | -5.1% | 7.9% | 9.3% | C |
| China Meheco 中国医药 | ¥133亿 | 30.9x | 1.1x | -0.7% | 1.8% | 2.1% | D |
| China National Accord Medicines 国药一致 | ¥119亿 | 11.1x | 0.6x | -1.4% | 1.8% | 3.2% | D |
| Lbx Pharmacy Chain 老百姓 | ¥98亿 | 22.8x | 1.4x | 2.1% | 4.8% | 6.6% | C |
| C.Q. Pharmaceutical Holding 重药控股 | ¥89亿 | 24.8x | 0.8x | -2.6% | 0.8% | 2.2% | E |
| Shanghai C&D Innostic Medical Technology 建发致新 | ¥83亿 | 29.7x | 3.8x | 1.8% | 1.9% | 6.8% | D |
| Nanjing Pharmaceutical Group 南京医药 | ¥64亿 | 10.2x | 0.9x | -0.5% | 1.4% | 4.0% | D |
| Yixintang Pharmaceutical Group 一心堂 | ¥62亿 | 22.9x | 0.8x | -5.0% | 3.1% | 3.5% | C |
| Guangxi Liuyao Group 柳药集团 | ¥60亿 | 9.3x | 0.8x | 2.2% | 3.5% | 4.6% | C |
| Shanghai Kai Kai 开开实业 | ¥40亿 | 171.3x | 5.0x | 5.8% | 5.1% | 2.8% | B |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。